AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02083120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long term Oxygen Therapy (LOT)
Description: Oxygen will individually be added to NHF in order to achieve stable oxygen saturation by pulse oximetry (SpO2) values of 88% to 92%.
Study NCT01373073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental human milk fortifier
Description: Human milk fortifier to be added to human milk feedings
Study NCT01373073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control human milk fortifier
Description: Control human milk fortifier to be added to human milk
Study NCT02775773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
Study NCT02775773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 2 vials (=10 IU/International Unit) of Oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
Study NCT02289573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA and PSV
Description: change ventilation modes(NAVA and PSV) with different support levels
Study NCT02289573 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NAVA and PSV
Description: change ventilation modes(NAVA and PSV) with different support levels
Study NCT00626626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofar, Cyclophos, Alemtuzumab
Description: Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 500 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion.
Study NCT00626626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofar, Cyclophos,Alemtuzumab(Ph II)
Description: Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 1000 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion (patients 4-9)
Study NCT02393027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [18F] LBT-999 PET
Study NCT02393027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] LBT-999 PET
Study NCT03971383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aolanti Weipang Tablets
Description: 3 tablets one time, 3 times a day(tid)
Study NCT03971383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets one time, 3 times a day(tid)
Study NCT01348568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low glycemic index diet with canola oil bread
Study NCT01348568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High fiber diet
Study NCT03130881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB1003
Description: PLB1003 is a capsule and is administered orally.
Study NCT05057780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Communication Skills Curriculum
Description: Our novel intervention adapted curricula around effective skills used to navigate common communication challenges in clinical practice. These skills were selected after determining patterns from multiple communication sessions delivered to over 6,000 healthcare providers. Our main goal was to enhance communication with patients by helping residents gain confidence and competence using these under-utilized communication skills, regardless of the communication challenge. Over the course of three, 1-hour long sessions on communication in the 2017-2018 academic year, internal medicine residents learned three of these highly effective and often under-utilized skills; reflective listening, responding to emotion and reframing, respectively.
Study NCT05057780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Skills Curriculum
Description: Our novel intervention adapted curricula around effective skills used to navigate common communication challenges in clinical practice. These skills were selected after determining patterns from multiple communication sessions delivered to over 6,000 healthcare providers. Our main goal was to enhance communication with patients by helping residents gain confidence and competence using these under-utilized communication skills, regardless of the communication challenge. Over the course of three, 1-hour long sessions on communication in the 2017-2018 academic year, internal medicine residents learned three of these highly effective and often under-utilized skills; reflective listening, responding to emotion and reframing, respectively.
Study NCT05228743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparing Hyperthermic Intraperitoneal Chemotherapy
Description: After laparoscopic exploration, HIPEC was started immediately: the temperature was 43 ℃ and the duration was 60 min. paclitaxel (PTX) was used with a dose of 50mg / m2. The second HIPEC was completed 24-48 hrs after the first HIPEC, and at least 4 HIPEC was completed.
Study NCT05228743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: A natural anticancer drug that has been widely used in the treatment of breast, ovarian and some head and neck and lung cancers.Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
Study NCT05228743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
Study NCT02757872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day
Study NCT02757872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty acids
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
Study NCT02757872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D3 placebo
Study NCT02757872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D3 placebo
Study NCT02757872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT02757872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT03693326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 300 mg (fixed dose) intraveneously every 3 weeks
Study NCT04399759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach-Instrumental Activities of Daily Living
Description: Individualized instrumental activities of daily living training
Study NCT04399759 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home health education
Description: Individualized home health education
Study NCT02065687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02065687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT02065687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02065687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02065687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO
Study NCT02065687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02065687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT02065687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT02065687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02065687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02065687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02065687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01569477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for abstinence and treatment engagement
Description: Treatment incentives - incentives for biochemical verification visits, treatment engagement and abstinence
Study NCT01569477 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attendance incentive
Description: Attendance Incentives - incentives for only attending the biochemical verification visits
Study NCT01180205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Telmisartan (80 mg ,Tablets, QD, p.o., 26 weeks)
Study NCT01180205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodpine 5 mg po 14 days, the forced - titration to 10 mg po for 24 weeks
Study NCT01180205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil
Description: Olmesartan 40 mg po for 26 weeks
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for estradiol at ET
Description: Blood test
Study NCT01180205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: HCT 12,5 mg po for 14 days, then 25 mg po for 24 weeks
Study NCT04585867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for estradiol at coordination scan
Description: Blood test
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial blood flow (doppler) at HCG
Description: Ultrasound scan
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial blood flow (doppler) at TVOR
Description: Ultrasound scan
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial blood flow (doppler) at ET
Description: Ultrasound scan
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial blood flow (doppler) at coordination scan
Description: Ultrasound scan
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Contractility at embryo transfer on a subgroup of participants
Description: Ultrasound scan
Study NCT04585867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
Study NCT04560010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injection (TXA)
Description: Injection of 1 gram of IV TXA before surgical plus 1 gram of IV TXA three hours later
Study NCT03746782 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytrometry; Thrombin Generation Assay
Description: Apixaban combined with blood specimens (in vitro) of study participants
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Change in endometrial pattern between coordination scan and ET
Description: Ultrasound scan
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Change in endometrial pattern between HCG and ET
Description: Ultrasound scan
Study NCT03838120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Procedure/Surgery: bupivakain % 0,5
Description: In this study, 5 patients were included in each volume group and at least 3 applications out of 5 had to be successful to consider the volume to be sufficient. After a successful group, the volume was reduced by 2 ml's and the same procedure was followed until a final group with unsuccessful anesthesia was found (≤2 successful blockades). The study was ended at this point and MEV was determined as the volume used in the last successful group. The researcher which determined the success of blockade was blinded to the study protocol. BMI, ASA Score, Successful blockade onset time Regression time of sensorial blockade Regression time of motor blockade Time of first additional analgesic requirement
Study NCT00564889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 300 mg/m\^2 days 1, 8 \& 15 of a 28 day cycle taken orally with food
Study NCT00564889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg weekly taken orally
Study NCT00564889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 15 mg daily days 1-21 of a 28 day cycle taken orally with food
Study NCT04996732 — intervention group
Intervention type: PROCEDURE
Intervention: hospitalization
Description: Including various treatments such as surgery, radiotherapy, chemotherapy and immunotherapy during hospitalization
Study NCT02342470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug : Placebo
Study NCT02342470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMK-S005 1
Description: Drug : PMK-S005 1 (50mg)
Study NCT02342470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMK-S005 2
Description: Drug : PMK-S005 2 (100mg)
Study NCT02342470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMK-S005 3
Description: Drug : PMK-S005 3 (150mg)
Study NCT04611308 — intervention group
Intervention type: OTHER
Intervention: C1q tumor necrosis factor-related protein 6 levels
Description: C1q tumor necrosis factor-related protein 6 is a tumor marker
Study NCT02138708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological test of pulmonary endothelial
Study NCT01542827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofreeze
Description: The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
Study NCT01542827 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
Study NCT03393182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TLDG arm
Description: After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy(TLDG)
Study NCT02081417 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Seeking Safety
Description: SS is a present-focused clinical intervention designed to target trauma/PTSD and SUDs.
Study NCT02644291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: chewable mebendazole tablets that can also be crushed and mixed with food or drink to be taken daily with meals
Study NCT03393182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LADG arm
Description: After lymphadenectomy, gastrectomy and reconstruction procedure are performed extracorporeally through mini-laparotomy(LADG)
Study NCT00617279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GORE PROPATEN Vascular Graft
Description: Arterial Occlusion Bypass
Study NCT02722642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchial basal cells
Description: Patients will receive 10\^6 (1 million) /Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
Study NCT01141647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocational Rehabilitation
Description: SCI-VIP: PrOMOTE evidence-based supported employment implemented for Veterans with spinal cord injury or other available vocational services
Study NCT00393783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAB HER 2 (HERCEPTIN)
Description: Rat HER2 DNA will be delivered intramuscularly at four different dose levels (0.5mg, 1mg, 3mg, or 6mg) during weeks 1, 4, 7, 10 and 13 for five injections.
Study NCT02974439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LANDI-Amlodipine Besylate Tablet 5mg
Description: LANDI-Amlodipine Besylate Tablet 5mg is a generic product manufactured by YangTZE River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.
Study NCT00617279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Disadvantaged Autologous Vein Graft
Description: Arterial Occlusion Bypass
Study NCT01916200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Description: Paroxetine CR will be provided by GlaxoSmithKline (GSK) and be available as 12.5 mg over-encapsulated tablets with the research use only label outside the package. Paroxetine CR should be administered as a single daily dose, with or without food. The recommended initial dose is 25 mg/day. Patients were dosed in a range of 25 mg to 62.5 mg/day in the clinical trials demonstrating the effectiveness of paroxetine CR in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 25-mg dose may benefit from dose increases, in 12.5 mg/day increments, up to a maximum of 62.5 mg/day. Dose changes should occur at intervals of at least 1 week.
Study NCT02991001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided hydrodissection
Description: Ultrasound-guided hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
Study NCT02974439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norvasc Tablets 5mg
Description: Norvasc Tablet 5mg will be used as a comparator drug for the BE study.
Study NCT04080453 — intervention group
Intervention type: OTHER
Intervention: Septic shock
Description: Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.
Study NCT02991001 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ultrasound-guided injection
Description: Ultrasound-guided injection with 5cc normal saline at subcutaneous layer beyond carpal tunnel
Study NCT02991001 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound
Study NCT04080453 — intervention group
Intervention type: OTHER
Intervention: Systemic Inflammatory Response Syndrome
Description: Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.
Study NCT05441644 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bispectral index
Description: A new placemewnt to monitor intraoperative BIS
Study NCT05441644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index
Description: A new placemewnt to monitor intraoperative BIS
Study NCT00944515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet or syrup 3 days/week
Study NCT00944515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: azithromycin 3 days/week
Study NCT03908957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga68-Dolacga Injection
Description: Ga68-Dolacga Injection, 3.5±0.25 mCi, single dose iv
Study NCT04716335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMT
Description: DMT
Study NCT04716335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harmine
Description: Harmine